Show simple item record

dc.contributor.authorFERHATOĞLU, Ferhat
dc.contributor.authorBAŞARAN, Mert
dc.contributor.authorGulbas, Zafer
dc.contributor.authorIribas Celik, Ayca
dc.contributor.authorKHANMAMMADOV, Nıjat
dc.contributor.authorDOĞAN, İzzet
dc.contributor.authorPAKSOY, Nail
dc.date.accessioned2023-02-21T09:16:20Z
dc.date.available2023-02-21T09:16:20Z
dc.date.issued2022
dc.identifier.citationPAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., BAŞARAN M., "High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience", Medicine (United States), cilt.101, sa.49, 2022
dc.identifier.issn0025-7974
dc.identifier.othervv_1032021
dc.identifier.otherav_2b2b9975-7c69-4d16-9559-e2169f85b241
dc.identifier.urihttp://hdl.handle.net/20.500.12627/187336
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85144119296&origin=inward
dc.identifier.urihttps://doi.org/10.1097/md.0000000000032213
dc.description.abstract© 2022 Lippincott Williams and Wilkins. All rights reserved.The prognosis of patients with Ewing's sarcoma family of tumors (ESFT) relapse is poor; the 5-year overall survival (OS) is 13%. We evaluated the effectivity of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in adult patients with ESFT relapse. Between January 2010 and January 2021, we retrospectively analyzed 20 patients with ESFT who received HDT upon relapse. A combination of busulfan with melphalan was used as a conditioning regimen before ASCT. The median follow-up from diagnosis and from first relapse was 46.08 months (range; 10.71-186.87) and 14.41 months (range; 4.34-104.11), respectively. The median of age patients was 21.2 years (range, 17.6-25.3), and 10 (50%) patients were female. The tumor originated from the bone in 13 patients and soft tissue in 7 patients. Twelve patients had early (2 years) relapse. Before HDT, 13 (65%) and 7 (35%) patients had pulmonary and extrapulmonary metastasis, respectively. After induction chemotherapy, 14 patients achieved complete response. The median OS1 and OS2 were 51.6 months (95% confidence interval [CI], range: 16.2-87) and 15.7 months (95% CI, range: 10.2-21.2), respectively. The 1-, 2-, and 5-year OS rates were 50%, 30%, and 15%, respectively. One patient died (sepsis) 1 month after ASCT. In univariate analyses, a disease-free interval (DFI) of 2 years and complete response before transplantation.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectGenel Tıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.titleHigh-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience
dc.typeMakale
dc.relation.journalMedicine (United States)
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume101
dc.identifier.issue49
dc.contributor.firstauthorID4188137


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record